Answers are grounded in this paper and cite their sources.
Lactylation links cellular metabolism to histone regulation and nonhistone protein function; however, its functional consequences in atherosclerosis depend on the modified substrate, target residue, cell type, and disease stage. This narrative review distinguishes direct atherosclerosis evidence from cardiovascular but non-atherosclerosis evidence and cross-disease mechanistic context, framing mechanistic claims accordingly. Direct evidence in atherosclerosis implicates several pathogenic pathways, including endothelial H3K18 lactylation at NF-κB pathway and SNAI1 promoters, SLC22A6- and ACSS1-driven H3K9 lactylation, lactate- and AARS1-dependent FOXO1 lactylation under atheroprone flow, H4K12 lactylation at CDKN1A during endothelial senescence, and an H3K18 lactylation–METTL3 axis in macrophage ferroptosis. Conversely, direct evidence also supports atheroprotective pathways, notably nonhistone MeCP2 K271 lactylation in endothelial cells and macrophages. Observations from myocardial repair, valvular and medial calcification, aortic aneurysm, pulmonary hypertension, and oncology provide mechanistic context rather than direct proof of plaque-specific biology. Furthermore, we examine the interplay between lactylation and acetylation, methylation, and RNA modifications—including scenarios where lactylation functions upstream of acetylation—and critically evaluate the capabilities and limitations of current analytical methods. Key methodological considerations include lactyl-donor stoichiometry and site occupancy; antibody cross-reactivity; resolution of L-lactyl, D-lactyl, and carboxyethyl lysine isomers; mass-spectrometric site localization; chromatin profiling against matched acetylation controls; and stable-isotope tracing. Finally, we propose an integrative translational framework that pairs peripheral mononuclear cell and plaque sampling with single-cell and spatial multi-omics, strictly distinguishing lactate sensing from site-specific protein lactylation detection. To date, no clinically validated lactylation biomarker or lactylation-targeted therapy exists for atherosclerosis, and lactate abundance cannot be conflated with protein lactylation. Clinical translation ultimately requires site-specific causal validation in plaque-relevant models and prospective human cohorts.
No takes yet. Share an insight, caveat, or question.
Mi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: